| Recruiting | Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis NCT05911503 | Tianjin Medical University | EARLY_Phase 1 |
| Completed | Deep Learning-based System and AIDS-related Cytomegalovirus Retinitis NCT04831333 | Kuifang Du | — |
| Completed | Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care NCT01431326 | Daniel Benjamin | — |
| Completed | Efficacy of Elevated CD4 Counts on CMV Retinitis NCT00091884 | National Eye Institute (NEI) | — |
| Completed | Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration NCT01866397 | Medical University of Vienna | Phase 4 |
| Completed | Longitudinal Study of Ocular Complications of AIDS (LSOCA) NCT00000168 | Johns Hopkins Bloomberg School of Public Health | — |
| Completed | Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) NCT00000143 | Johns Hopkins Bloomberg School of Public Health | Phase 3 |
| Completed | Immune Activity Against CVM Retinitis NCT00001611 | National Eye Institute (NEI) | — |
| Completed | A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes NCT00002377 | Hoffmann-La Roche | Phase 3 |
| Completed | Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT) NCT00000135 | Johns Hopkins Bloomberg School of Public Health | Phase 2 / Phase 3 |
| Completed | Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis NCT00004794 | National Center for Research Resources (NCRR) | Phase 2 |
| Completed | Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) NCT00000134 | Johns Hopkins Bloomberg School of Public Health | Phase 3 |
| Completed | Ganciclovir Implant Study for Cytomegalovirus Retinitis NCT00000118 | National Eye Institute (NEI) | Phase 3 |
| Completed | Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT) NCT00000136 | Johns Hopkins Bloomberg School of Public Health | Phase 3 |
| Completed | An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children NCT00002015 | Roche Global Development | N/A |
| Completed | A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatenin NCT00000698 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Th NCT00002321 | Chiron Corporation | Phase 1 |
| Completed | Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis NCT00000894 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Withdrawn | A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Us NCT00000697 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in NCT00000688 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Ret NCT00002142 | Gilead Sciences | N/A |
| Completed | The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony St NCT00000989 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) NCT00000836 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised NCT00002025 | Hoffmann-La Roche | N/A |
| Completed | Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS NCT00001061 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | CMV Retinitis Retreatment Trial NCT00000766 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis NCT00002187 | Ionis Pharmaceuticals, Inc. | N/A |
| Completed | Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component NCT00000665 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Fosc NCT00002125 | Astra USA | Phase 4 |
| Completed | Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Pati NCT00000693 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients Wi NCT00002437 | Gilead Sciences | Phase 2 |
| Completed | A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes NCT00002355 | Ionis Pharmaceuticals, Inc. | N/A |
| Completed | A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cy NCT00002034 | Hoffmann-La Roche | N/A |
| Completed | A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patient NCT00002156 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Unknown | A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not NCT00002301 | Astra USA | N/A |
| Completed | A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Ne NCT00002257 | Hoffmann-La Roche | N/A |
| Completed | The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes NCT00002356 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Unknown | A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS NCT00002384 | Gilead Sciences | N/A |
| Completed | A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes NCT00001062 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir NCT00000668 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis NCT00002169 | Agouron Pharmaceuticals | Phase 2 |
| Withdrawn | A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease NCT00000881 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis NCT00002070 | Schering-Plough | Phase 3 |
| Completed | A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effe NCT00000905 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited V NCT00002135 | Hoffmann-La Roche | N/A |
| Completed | Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome NCT00000726 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threate NCT00000691 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AID NCT00002330 | Roche Global Development | N/A |
| Unknown | Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection NCT00017784 | Hoffmann-La Roche | Phase 3 |
| Completed | HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol NCT00000799 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune NCT00001999 | American National Red Cross | N/A |
| Completed | A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Gancic NCT00002247 | Hoffmann-La Roche | N/A |
| Completed | A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS NCT00002222 | Hoffmann-La Roche | N/A |
| Completed | A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS NCT00002432 | Astra USA | N/A |
| Completed | A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunct NCT00002134 | Roche Global Development | N/A |
| Completed | The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease NCT00001034 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients NCT00002039 | Astra USA | N/A |
| Completed | A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV NCT00000673 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus ( NCT00002299 | Hoffmann-La Roche | N/A |
| Completed | A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who NCT00000970 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Mono NCT00002016 | Sandoz | Phase 1 |
| Completed | A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection NCT00005572 | National Institute of Allergy and Infectious Diseases (NIAID) | — |